Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Amylin Pharmaceuticals, Inc. Eli Lilly and Company |
---|---|
Information provided by: | Amylin Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00044668 |
This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: AC2993 (synthetic exendin-4) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination |
Estimated Enrollment: | 150 |
Study Start Date: | August 2002 |
Ages Eligible for Study: | 20 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Hungary | |
Peterfy Teaching Hospital | |
Budapest, Hungary, H 1076 | |
Diagnostic Units Hungary Kft. | |
Budapest, Hungary, H 1036 | |
Uzsoki Street Municipal Hospital | |
Budapest, Hungary, H 1145 |
Study Director: | Lisa Porter, MD | Amylin Pharmaceuticals, Inc. |
Study ID Numbers: | 2993-117 |
Study First Received: | September 3, 2002 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00044668 |
Health Authority: | United States: Food and Drug Administration; Hungary: National Institute of Pharmacy |
exenatide exendin-4 diabetes Amylin Lilly |
Metabolic Diseases Exenatide Metformin Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |
Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |